Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMengjie DingFNFeifei Nan

Discussion

Loading...

Member takes

Overview

Real-world analysis shows improved progression-free survival in high-risk B-cell lymphoma, indicating CAR-T therapy's potential benefits.

Key Points

  • Patients receiving CAR T cell therapy achieved a complete metabolic response rate of 100% within one month after infusion.
  • The 18-month overall survival and progression-free survival rates were both observed at 100% in this cohort.
  • This real-world case series study assessed six patients with B-cell lymphoma undergoing consolidation with CAR-T therapy.
  • Results highlight the manageable safety profile of CAR T therapy, with mild adverse events including cytokine release syndrome present in all patients.

Cite This Study

Ding et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc33https://doi.org/10.1182/blood-2025-8015
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience2025
  2. 2Prognostic impact of CAR-T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel2025
  3. 3Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study2025
  4. 4Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries2025
  5. 5Azer-cel, an allogeneic (allo) CD19 CAR T, in combination with low-dose interleukin-2 (IL-2) demonstrates clinical activity in patients with large B-cell lymphoma (LBCL) who relapsed after autologous (auto) CAR T2025